TheraDiag's $210M Bet on a New Class of Targeted Degraders

THESIS — TheraDiag is positioned to deliver outsized returns by advancing a first-in-class protein degrader into registrational studies for genetically defined solid tumors. THE SCIENCE — The company's lead asset, TD-101, is an oral PROTAC (proteolysis-targeting chimera) designed to degrade the transcription factor MYC, a historically 'undruggable' driver of numerous cancers. TD-101 binds both MYC and an E3 ubiquitin ligase, tagging MYC for destruction by the cell's own proteasome machinery. This mechanism offers a potentially more complete and durable inhibition than traditional small molecules targeting upstream pathways. WHY NOW — The capital raise is timed ahead of the pivotal Phase 3 ORION-2 trial readout in MYC-amplified gastric cancer, expected in late 2026. Recent Phase 2 data showed a 35% objective response rate in a heavily pre-treated population, crossing the threshold of clinical meaningfulness that de-risks the pivotal study design and validates the degradation approach. THE CAPITAL — Deutsche Bank led this $210M public offering, a significant show of institutional support for a single-asset, clinical-stage biotech. Their involvement signals a belief in the program's maturity and the near-term catalyst value of the upcoming trial. RISK/REWARD — The key risk is the binary outcome of ORION-2; failure would likely erase most of the company's value. The upside, however, is substantial: success not only unlocks a $2B+ initial market in gastric cancer but also validates the platform for a broad pipeline in other MYC-driven malignancies, potentially creating a multi-billion dollar franchise.